S&P 500   4,640.89 (+1.62%)
DOW   34,924.20 (+1.28%)
QQQ   397.09 (+0.83%)
AAPL   168.03 (+1.65%)
MSFT   334.16 (+1.08%)
FB   325.41 (+0.29%)
GOOGL   2,903.44 (+2.31%)
AMZN   3,529.50 (+0.64%)
TSLA   1,150.50 (+0.50%)
NVDA   326.98 (+0.07%)
BABA   127.16 (-0.29%)
NIO   39.95 (+2.10%)
CGC   10.69 (-0.19%)
AMD   157.03 (-0.85%)
GE   95.71 (+0.76%)
MU   87.74 (+4.45%)
T   22.94 (+0.48%)
F   20.25 (+5.52%)
DIS   147.05 (+1.48%)
ACB   6.39 (-0.47%)
PFE   53.53 (-0.37%)
AMC   33.83 (-0.32%)
BA   198.31 (+0.23%)
S&P 500   4,640.89 (+1.62%)
DOW   34,924.20 (+1.28%)
QQQ   397.09 (+0.83%)
AAPL   168.03 (+1.65%)
MSFT   334.16 (+1.08%)
FB   325.41 (+0.29%)
GOOGL   2,903.44 (+2.31%)
AMZN   3,529.50 (+0.64%)
TSLA   1,150.50 (+0.50%)
NVDA   326.98 (+0.07%)
BABA   127.16 (-0.29%)
NIO   39.95 (+2.10%)
CGC   10.69 (-0.19%)
AMD   157.03 (-0.85%)
GE   95.71 (+0.76%)
MU   87.74 (+4.45%)
T   22.94 (+0.48%)
F   20.25 (+5.52%)
DIS   147.05 (+1.48%)
ACB   6.39 (-0.47%)
PFE   53.53 (-0.37%)
AMC   33.83 (-0.32%)
BA   198.31 (+0.23%)
S&P 500   4,640.89 (+1.62%)
DOW   34,924.20 (+1.28%)
QQQ   397.09 (+0.83%)
AAPL   168.03 (+1.65%)
MSFT   334.16 (+1.08%)
FB   325.41 (+0.29%)
GOOGL   2,903.44 (+2.31%)
AMZN   3,529.50 (+0.64%)
TSLA   1,150.50 (+0.50%)
NVDA   326.98 (+0.07%)
BABA   127.16 (-0.29%)
NIO   39.95 (+2.10%)
CGC   10.69 (-0.19%)
AMD   157.03 (-0.85%)
GE   95.71 (+0.76%)
MU   87.74 (+4.45%)
T   22.94 (+0.48%)
F   20.25 (+5.52%)
DIS   147.05 (+1.48%)
ACB   6.39 (-0.47%)
PFE   53.53 (-0.37%)
AMC   33.83 (-0.32%)
BA   198.31 (+0.23%)
S&P 500   4,640.89 (+1.62%)
DOW   34,924.20 (+1.28%)
QQQ   397.09 (+0.83%)
AAPL   168.03 (+1.65%)
MSFT   334.16 (+1.08%)
FB   325.41 (+0.29%)
GOOGL   2,903.44 (+2.31%)
AMZN   3,529.50 (+0.64%)
TSLA   1,150.50 (+0.50%)
NVDA   326.98 (+0.07%)
BABA   127.16 (-0.29%)
NIO   39.95 (+2.10%)
CGC   10.69 (-0.19%)
AMD   157.03 (-0.85%)
GE   95.71 (+0.76%)
MU   87.74 (+4.45%)
T   22.94 (+0.48%)
F   20.25 (+5.52%)
DIS   147.05 (+1.48%)
ACB   6.39 (-0.47%)
PFE   53.53 (-0.37%)
AMC   33.83 (-0.32%)
BA   198.31 (+0.23%)
OTCMKTS:CYDY

CytoDyn Stock Forecast, Price & News

$1.25
+0.07 (+5.93%)
(As of 11/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.18
$1.26
50-Day Range
$1.14
$2.46
52-Week Range
$1.08
$7.40
Volume
1.21 million shs
Average Volume
3.13 million shs
Market Capitalization
$839.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-1.06
30 days | 90 days | 365 days | Advanced Chart
Receive CYDY News and Ratings via Email

Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter.


CytoDyn logo

About CytoDyn

CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, Cancer, graft-versus-host disease (GVHD), and COVID-19. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CYDY
Previous Symbol
NASDAQ:CYDY
CUSIP
23283M101
Fax
N/A
Employees
19
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
($0.03) per share

Profitability

Net Income
$-154.67 million
Pretax Margin
-377,514.59%

Debt

Price-To-Earnings

Miscellaneous

Free Float
619,370,000
Market Cap
$839.71 million
Optionable
Not Optionable

Company Calendar

Last Earnings
10/12/2021
Today
12/01/2021
Fiscal Year End
5/31/2022

MarketRank

Overall MarketRank

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












CytoDyn (OTCMKTS:CYDY) Frequently Asked Questions

How has CytoDyn's stock been impacted by Coronavirus (COVID-19)?

CytoDyn's stock was trading at $1.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CYDY stock has increased by 21.4% and is now trading at $1.25.
View which stocks have been most impacted by COVID-19
.

How were CytoDyn's earnings last quarter?

CytoDyn Inc. (OTCMKTS:CYDY) released its earnings results on Tuesday, October, 12th. The biotechnology company reported ($0.05) EPS for the quarter. The biotechnology company had revenue of $0.04 million for the quarter.
View CytoDyn's earnings history
.

Who are CytoDyn's key executives?

CytoDyn's management team includes the following people:
  • Scott A. Kelly, Chairman & Chief Medical Officer
  • Nader Z. Pourhassan, President, Chief Executive Officer & Director
  • Nitya G. Ray, Chief Operating Officer
  • Antonio Migliarese, Chief Financial Officer & Treasurer
  • Christopher P. Recknor, Senior EVP-Clinical Operations

What other stocks do shareholders of CytoDyn own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytoDyn investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), NVIDIA (NVDA), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Vaxart (VXRT), Nokia (NOK), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Moderna (MRNA).

What is CytoDyn's stock symbol?

CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY."

How do I buy shares of CytoDyn?

Shares of CYDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CytoDyn's stock price today?

One share of CYDY stock can currently be purchased for approximately $1.25.

How much money does CytoDyn make?

CytoDyn has a market capitalization of $839.71 million. The biotechnology company earns $-154.67 million in net income (profit) each year or ($0.27) on an earnings per share basis.

How many employees does CytoDyn have?

CytoDyn employs 19 workers across the globe.

What is CytoDyn's official website?

The official website for CytoDyn is www.cytodyn.com.

Where are CytoDyn's headquarters?

How can I contact CytoDyn?

CytoDyn's mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The biotechnology company can be reached via phone at (360) 980-8524 or via email at [email protected].


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.